drugset / Trial / NCT00598312

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

NCT00598312

Phase 3 Completed 201 enrolled Oakwood Laboratories, LLC
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for Injectable Suspension 22.5 mg in reducing serum testosterone to castrate levels in patients with prostate cancer.

Timeline

Start
2007-04
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 22.5 mg

Indications